These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 35393160)

  • 21. Useful predictors of progression-free survival for Japanese patients with LATITUDE-high-risk metastatic castration-sensitive prostate cancer who received upfront abiraterone acetate.
    Takahara K; Naiki T; Ito T; Nakane K; Koie T; Yasui T; Miyake H; Shiroki R
    Int J Urol; 2022 Mar; 29(3):229-234. PubMed ID: 34863085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
    Fizazi K; Tran N; Fein L; Matsubara N; Rodriguez-Antolin A; Alekseev BY; Özgüroğlu M; Ye D; Feyerabend S; Protheroe A; Sulur G; Luna Y; Li S; Mundle S; Chi KN
    Lancet Oncol; 2019 May; 20(5):686-700. PubMed ID: 30987939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combining prostate cancer radiotherapy with therapies targeting the androgen receptor axis.
    Ghashghaei M; Kucharczyk M; Elakshar S; Muanza T; Niazi T
    Curr Oncol; 2019 Oct; 26(5):e640-e650. PubMed ID: 31708657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
    Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
    Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Department of Medicine; Department of Biostatistics and Computational Biology; Dana-Farber Cancer Institute, Boston; Harvard Medical School, Boston; Johns Hopkins University, Baltimore; University of Wisconsin Carbone Cancer Center; School of Medicine and Public Health; Madison; Fox Chase Cancer Center, Temple University Health System, Philadelphia; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis; Mayo Clinic, Rochester, MN; University Hospitals Case Medical Center, Seidman Cancer Center; Cleveland Clinic Taussig Cancer Institute; Both in Cleveland; University of Virginia Cancer Center, Charlottesville; Comprehensive Cancer Centers of Nevada, Las Vegas; Siteman Cancer Center, Washington University School of Medicine, St. Louis; NorthShore University Health System, Evanston, IL; University of Michigan Comprehensive Cancer Center, Ann Arbor; Rutgers Cancer Institute of New Jersey, New Brunswick.N Engl J Med. 2015 Aug 20;373(8):737-46. [Epub 2015 Aug 5]. doi: 10.1056/NEJMoa1503747.
    Scott E
    Urol Oncol; 2017 Mar; 35(3):123. PubMed ID: 28159490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Re: Shusuke Akamatsu, Masashi Kubota, Ryuji Uozumi, et al. Development and Validation of a Novel Prognostic Model for Predicting Overall Survival in Treatment-naïve Castration-sensitive Metastatic Prostate Cancer. Eur Urol Oncol 2019;2:320-328.
    Mazzone E; Karakiewicz PI
    Eur Urol Oncol; 2019 May; 2(3):338-339. PubMed ID: 31200851
    [No Abstract]   [Full Text] [Related]  

  • 27. Commentary on: "Inherited DNA-repair gene mutations in men with metastatic prostate cancer." Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016 Aug 4;375(5):443-53.
    Lee BH
    Urol Oncol; 2017 Sep; 35(9):575-576. PubMed ID: 28789927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Commentary on "Inherited DNA-repair gene mutations in men with metastatic prostate cancer". Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016;375(5):443-53.
    Freedland SJ; Aronson WJ
    Urol Oncol; 2017 Aug; 35(8):536-537. PubMed ID: 28623070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Darolutamide in Metastatic Prostate Cancer.
    Turco F; Tucci M; Buttigliero C
    N Engl J Med; 2022 Jun; 386(24):2344. PubMed ID: 35704492
    [No Abstract]   [Full Text] [Related]  

  • 30. Darolutamide in Metastatic Prostate Cancer.
    Bowling GC; Dimitrakoff JD
    N Engl J Med; 2022 Jun; 386(24):2344. PubMed ID: 35704493
    [No Abstract]   [Full Text] [Related]  

  • 31. The optimal treatment of metastatic hormone-naive prostate cancer: abiraterone acetate or docetaxel?
    Aoun F; El Rassy E; Sleilaty G; Assi T; Bakouny Z; Kattan J
    Future Oncol; 2017 Dec; 13(30):2785-2790. PubMed ID: 29188727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cases in the management of prostate cancer: the addition of darolutamide to androgen deprivation therapy and docetaxel in a 55-year-old man with metastatic hormone-sensitive prostate cancer.
    Crawford ED
    Clin Adv Hematol Oncol; 2022 Jul; 20 Suppl 14(7):1-8. PubMed ID: 35905311
    [No Abstract]   [Full Text] [Related]  

  • 33. Re: Nobuaki Matsubara, Kim N. Chi, Mustafa Özgüroğlu, et al. Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study. Eur Urol. 2020:77:494-500. https://doi.org/10.1016/j.eururo.2019.11.021.
    Hess BA
    Eur Urol; 2020 Aug; 78(2):e89-e90. PubMed ID: 32291107
    [No Abstract]   [Full Text] [Related]  

  • 34. Darolutamide in Metastatic Prostate Cancer. Reply.
    Smith MR
    N Engl J Med; 2022 Jun; 386(24):2345. PubMed ID: 35704494
    [No Abstract]   [Full Text] [Related]  

  • 35. A drug safety evaluation of abiraterone acetate in the treatment of prostate cancer.
    Castellan P; Castellucci R; Marchioni M; De Nunzio C; Tema G; Primiceri G; Schips L; Cindolo L
    Expert Opin Drug Saf; 2019 Sep; 18(9):759-767. PubMed ID: 31353982
    [No Abstract]   [Full Text] [Related]  

  • 36. Recent trends in the management of advanced prostate cancer.
    Ritch C; Cookson M
    F1000Res; 2018; 7():. PubMed ID: 30345007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction.
    Flaig TW; Plets M; Hussain MHA; Agarwal N; Mitsiades N; Deshpande HA; Vaishampayan UN; Thompson IM
    JAMA Oncol; 2017 Nov; 3(11):e170231. PubMed ID: 28358937
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive factors for the efficacy of abiraterone acetate therapy in high-risk metastatic hormone-sensitive prostate cancer patients.
    Ueda T; Fujita K; Nishimoto M; Shiraishi T; Miyashita M; Kayukawa N; Nakamura Y; Sako S; Ogura R; Fujihara A; Minami T; Hongo F; Okihara K; Yoshimura K; Uemura H; Ukimura O
    World J Urol; 2022 Dec; 40(12):2939-2946. PubMed ID: 36331614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Abiraterone acetate: a guide to its use in metastatic castration-resistant prostate cancer.
    Scott LJ; Yang LPH; Lyseng-Williamson KA
    Drugs Aging; 2012 Mar; 29(3):243-248. PubMed ID: 22372727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy.
    Kassem L; Shohdy KS; Abdel-Rahman O
    Curr Med Res Opin; 2018 May; 34(5):903-910. PubMed ID: 29490505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.